Journal of Clinical Endocrinology & Metabolism, Vol 81, 2607-2612, Copyright © 1996 by Endocrine Society

ARTICLES

Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines

K Ohta, XP Pang, L Berg and JM Hershman
Endocrine Research Laboratory, West Los Angeles Veterans Affairs Medical Center, California 90073, USA.

To investigate the in vitro effects of cytokines on the growth of human papillary thyroid carcinoma (PTC) cells, we established six new PTC cell lines, designated BHP 5, 14, 15, 17, 18, and 19, from different patients. We studied the antiproliferative actions of cytokines by using BHP cells, NP cells (PTC cell line), and ARO cells (anaplastic thyroid carcinoma cell line). These cells were treated with various concentrations of tumor necrosis factor-alpha (TNF alpha), interferon- gamma (IFN gamma), interleukin-1 beta (IL-1 beta), and transforming growth factor-beta 1 (TGF beta 1), alone and in combination. Cell proliferation was assessed by [3H]thymidine incorporation and cell number measurement. In BHP cell lines, IFN gamma, IL-1 beta, and TGF beta 1 inhibited [3H]thymidine incorporation and decreased cell number, but TNF alpha stimulated [3H]thymidine incorporation. In NP cells, treatment with each cytokine decreased [3H]thymidine incorporation and cell number. In contrast, the proliferation of ARO cells was either stimulated by or resistant to TNF alpha, IL-1 beta, and TGF beta 1. The effects of these cytokines on [3H]thymidine incorporation were additive in these cell lines. The results suggest that IL-1 beta and TGF beta 1 play a pivotal role in growth inhibition of PTC cells, and the escape from negative control of IL-1 beta and TGF beta 1 may be a step toward anaplastic changes. The additive effects of these cytokines suggest that they act through different pathways.

This article has been cited by other articles:

				R. E. Schweppe, J. P. Klopper, C. Korch, U. Pugazhenthi, M. Benezra, J. A. Knauf, J. A. Fagin, L. A. Marlow, J. A. Copland, R. C. Smallridge, et al. Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4331 - 4341. [Abstract] [Full Text] [PDF]

				Y. C. Henderson, S.-H. Ahn, Y. Kang, and G. L. Clayman Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement Clin. Cancer Res., August 1, 2008; 14(15): 4908 - 4914. [Abstract] [Full Text] [PDF]

				M Celano, S Schenone, D Cosco, M Navarra, E Puxeddu, L Racanicchi, C Brullo, E Varano, S Alcaro, E Ferretti, et al. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo Endocr. Relat. Cancer, June 1, 2008; 15(2): 499 - 510. [Abstract] [Full Text] [PDF]

				T. Endo, K. Ohta, and T. Kobayashi Expression and Function of Cbfa-1/Runx2 in Thyroid Papillary Carcinoma Cells J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2409 - 2412. [Abstract] [Full Text] [PDF]

				M. S. Fenton, K. M. Marion, and J. M. Hershman Identification of Cyclic Adenosine 3',5'-Monophosphate Response Element Modulator as an Activator of the Human Sodium/Iodide Symporter Upstream Enhancer Endocrinology, May 1, 2008; 149(5): 2592 - 2606. [Abstract] [Full Text] [PDF]

				Y. C. Henderson, M. J. Fredrick, and G. L. Clayman Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors Arch Otolaryngol Head Neck Surg, August 1, 2007; 133(8): 810 - 815. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078. [Abstract] [Full Text] [PDF]

				Q. T. Luong, J. O'Kelly, G. D. Braunstein, J. M. Hershman, and H. P. Koeffler Antitumor Activity of Suberoylanilide Hydroxamic Acid against Thyroid Cancer Cell Lines In vitro and In vivo. Clin. Cancer Res., September 15, 2006; 12(18): 5570 - 5577. [Abstract] [Full Text] [PDF]

				T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]

				S. E. Matsuo, S. G. Leoni, A. Colquhoun, and E. T. Kimura Transforming growth factor-{beta}1 and activin A generate antiproliferative signaling in thyroid cancer cells. J. Endocrinol., July 1, 2006; 190(1): 141 - 150. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, V. Poulaki, G. Fanourakis, E. Sozopoulos, D. McMillin, Z. Wen, G. Voutsinas, S. Tseleni-Balafouta, and N. Mitsiades Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin. Cancer Res., June 15, 2006; 12(12): 3705 - 3712. [Abstract] [Full Text] [PDF]

				T. Kogai, Y. Kanamoto, A. I. Li, L. H. Che, E. Ohashi, K. Taki, R. A. Chandraratna, T. Saito, and G. A. Brent Differential Regulation of Sodium/Iodide Symporter Gene Expression by Nuclear Receptor Ligands in MCF-7 Breast Cancer Cells Endocrinology, July 1, 2005; 146(7): 3059 - 3069. [Abstract] [Full Text] [PDF]

				K. Taki, T. Kogai, Y. Kanamoto, J. M. Hershman, and G. A. Brent A Thyroid-Specific Far-Upstream Enhancer in the Human Sodium/Iodide Symporter Gene Requires Pax-8 Binding and Cyclic Adenosine 3',5'-Monophosphate Response Element-Like Sequence Binding Proteins for Full Activity and Is Differentially Regulated in Normal and Thyroid Cancer Cells Mol. Endocrinol., October 1, 2002; 16(10): 2266 - 2282. [Abstract] [Full Text] [PDF]

				K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya Ligands for Peroxisome Proliferator-Activated Receptor {{gamma}} Inhibit Growth and Induce Apoptosis of Human Papillary Thyroid Carcinoma Cells J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2170 - 2177. [Abstract] [Full Text]

				J. Kurebayashi, K. Tanaka, T. Otsuki, T. Moriya, H. Kunisue, M. Uno, and H. Sonoo All-Trans-Retinoic Acid Modulates Expression Levels of Thyroglobulin and Cytokines in a New Human Poorly Differentiated Papillary Thyroid Carcinoma Cell Line, KTC-1 J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2889 - 2896. [Abstract] [Full Text]

				S. G. Ren, J. Seliktar, X. Li, J. M. Hershman, G. D. Braunstein, and S. Melmed In Vivo and in Vitro Regulation of Thyroid Leukemia Inhibitory Factor (LIF): Marker of Hypothyroidism J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2883 - 2887. [Abstract] [Full Text]

				C. A. Muro-Cacho, T. Munoz-Antonia, S. Livingston, and D. Klotch Transforming Growth Factor {beta} Receptors and p27kip in Thyroid Carcinoma Arch Otolaryngol Head Neck Surg, January 1, 1999; 125(1): 76 - 81. [Abstract] [Full Text] [PDF]

				L. Fiore, L. E. Pollina, G. Fontanini, R. Casalone, M. T. Berlingieri, R. Giannini, F. Pacini, P. Miccoli, A. Toniolo, A. Fusco, et al. Cytokine Production by a New Undifferentiated Human Thyroid Carcinoma Cell Line, FB-1 J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4094 - 4100. [Abstract] [Full Text] [PDF]

				K. Ohta, X.-P. Pang, L. Berg, and J. M. Hershman Growth Inhibition of New Human Thyroid Carcinoma Cell Lines by Activation of Adenylate Cyclase through the {beta}-Adrenergic Receptor J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2633 - 2638. [Abstract] [Full Text] [PDF]